Skipjack tuna bone-derived biocalcium ameliorates osteoblast and osteoclast differentiation through microRNA21 regulation

Information from the abstract

Alternative calcium sources are needed to enhance osteoporosis management. This study investigated the osteoprotective effects of skipjack tuna bone-derived biocalcium (Bio). Bio enhanced MC3T3-E1 osteoblast and C3H10T1/2 cell differentiation, increasing alkaline phosphatase activity and calcium deposition. Conversely, Bio inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in RAW 264.7 macrophages, reducing tartrate-resistant acid phosphatase (TRAP) activity and bone resorption. Bio suppressed intracellular ROS and downregulated primary, precursor and mature microRNA (miR)-21. miR-21 inhibitor suppressed TRAP activity and Cathepsin K expression, as opposed to miR-21 mimic. In an osteoblast-osteoclast crosstalk environment, Bio synergistically enhanced miR-21 target genes (PTEN and PDCD4) expression, whereas PTEN knockdown suppressed NFATc1 osteoclast marker expression via miR-21 inhibition. Molecular docking confirmed binding affinities between mouse and human miR-21 and both targets. Western blot showed β-catenin upregulation and total NF-κB p65 suppression after Bio treatment. Collectively, Bio exerts dual anti-osteoporotic actions, offering a potential functional supplement for bone remodeling disorders.

Why this record is monitored

This record has an Impact Signal of 74/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.

Related topics: Bone Metabolism and Diseases · Bone health and osteoporosis research · Bone Tissue Engineering Materials